Residency · Residency · Geriatrics

Diabetes Management in Older Adults

Introduction

Diabetes mellitus represents one of the most prevalent and consequential chronic diseases affecting the geriatric population, with an estimated 25 to 33 percent of adults aged 65 and older carrying a diagnosis of diabetes or harboring undiagnosed disease. Type 2 diabetes mellitus accounts for more than 95 percent of diabetes in this age group, although the population of elderly individuals living with type 1 diabetes is steadily growing as advances in insulin therapy and glucose monitoring technology have extended survival considerably. The clinical management of diabetes in older adults demands a fundamentally different approach from that applied to younger patients, as elderly individuals with diabetes face a constellation of interrelated risks that extend far beyond glycemic control. These patients experience markedly increased vulnerability to hypoglycemia, falls, cognitive decline, depression, urinary incontinence, functional impairment, and the cascading complications of polypharmacy.

Both the American Diabetes Association and the Endocrine Society have issued guidelines that emphasize the paramount importance of individualized glycemic targets. These targets must be calibrated to the patient's overall health status, functional capacity, estimated life expectancy, and personal preferences. The principle of individualization reflects a growing recognition that overtreatment of diabetes in the elderly, particularly the pursuit of tight glycemic control in frail individuals, frequently causes more harm than benefit. Hypoglycemia emerges as a major driver of morbidity and mortality in this population, and the geriatrician must maintain a constant awareness of its risks when making therapeutic decisions.

Glycemic Targets — Individualization is Key

ADA Framework (2024)

The American Diabetes Association's 2024 Standards of Care provide a stratified framework for glycemic targets that categorizes elderly patients into three health status groups. For healthy older adults with few comorbidities, intact cognition, and good functional status, a hemoglobin A1c target of less than 7.0 to 7.5 percent is considered appropriate. This cohort is most likely to derive long-term benefit from glycemic optimization, as their life expectancy is sufficient to realize the microvascular and macrovascular advantages of glucose control. For patients with complex or intermediate health status, defined by the presence of multiple comorbidities, two or more impairments in activities of daily living, or mild-to-moderate cognitive impairment, a less stringent target of less than 8.0 percent is recommended. This relaxation acknowledges the diminishing returns of tight control in patients whose competing health burdens may limit life expectancy and whose physiological vulnerability to hypoglycemia is heightened.

For patients in very complex or poor health, including those with end-stage comorbidities, advanced dementia, or limited life expectancy, the recommended hemoglobin A1c target is less than 8.5 percent, or management may be guided entirely by the avoidance of hypoglycemia and symptomatic hyperglycemia rather than by any specific A1c number. In this most frail cohort, the goals shift decisively toward comfort, safety, and preservation of quality of life. A critically important boundary is the avoidance of hemoglobin A1c levels below 6.5 percent in elderly patients, a threshold associated with increased hypoglycemia, falls, and mortality. The ACCORD trial demonstrated that intensive glycemic control targeting an A1c below 6.0 percent increased all-cause mortality by 22 percent in high-risk patients, a finding that profoundly reshaped the approach to diabetes management in vulnerable populations.

Hypoglycemia — The Primary Safety Concern

Hypoglycemia stands as the foremost safety concern in elderly diabetes management, reflecting the convergence of age-related physiological changes that amplify both the likelihood and the consequences of low blood glucose. Older adults exhibit impaired counter-regulatory hormonal responses, with diminished glucagon and epinephrine secretion during hypoglycemia. This blunted hormonal response translates into reduced symptom awareness, a phenomenon termed hypoglycemia unawareness, which deprives the patient of the warning signals that would normally prompt corrective action.

The downstream consequences of hypoglycemia in elderly patients are both severe and diverse. Falls are approximately twice as likely in the setting of hypoglycemia, and falls may lead to fractures, head injuries, and prolonged hospitalizations. Hypoglycemia precipitates delirium, seizures, cardiac arrhythmias, myocardial infarction, and accelerated cognitive decline. In the context of the ACCORD trial, intensive control targeting A1c below 6.0 percent was associated with excess mortality, with hypoglycemia identified as a major contributing factor. The medications most likely to cause hypoglycemia include insulin, sulfonylureas (particularly glyburide, which possesses a prolonged duration of action and active metabolites), and meglitinides. Glyburide, also known as glibenclamide, is explicitly listed as a drug to avoid in the elderly under the American Geriatrics Society Beers Criteria due to its disproportionate hypoglycemia risk among sulfonylureas. When a sulfonylurea is necessary, glipizide or glimepiride should be substituted.

CGM and Glucose Monitoring

Continuous glucose monitoring technology is increasingly utilized in elderly patients and offers several advantages over traditional self-monitoring of blood glucose. CGM provides continuous data streams that enable clinicians to assess time in range, time below range, and time above range, each of which carries specific targets adapted for the geriatric population. For complex elderly patients, a time in range (glucose 70 to 180 mg/dL) target of greater than 50 percent is appropriate, while healthier elderly individuals may aim for greater than 70 percent. The time below range (glucose less than 70 mg/dL) target should be less than 1 percent, reflecting the absolute priority of minimizing hypoglycemia. Time above range (glucose greater than 250 mg/dL) should be maintained below 10 percent to prevent symptomatic hyperglycemia and its attendant complications of polyuria, dehydration, and impaired wound healing.

The WISDM trial provided pivotal evidence that CGM reduces hypoglycemia in older adults on insulin therapy. In adults aged 60 and older treated with insulin, CGM reduced hypoglycemia by approximately 50 percent, a clinically meaningful benefit that has expanded the role of this technology in geriatric diabetes care. For patients managed on agents that do not cause hypoglycemia, less frequent self-monitoring of blood glucose is acceptable and avoids unnecessary burden.

<image>A glycemic target individualization framework for elderly diabetes patients. Show three columns representing patient categories: HEALTHY (few comorbidities, independent, intact cognition), COMPLEX (multiple comorbidities, some ADL dependency, mild-moderate cognitive impairment), and VERY COMPLEX/POOR HEALTH (end-stage disease, advanced dementia, limited life expectancy). For each column, display: HbA1c target (7-7.5%, <8%, <8.5%), fasting glucose range (80-130, 90-150, 100-180 mg/dL), bedtime glucose range (90-150, 100-180, 110-200 mg/dL), and hypoglycemia avoidance priority (important, very important, paramount). Show CGM targets for each: TIR goal, time below range goal. Include a warning triangle at the bottom stating "AVOID HbA1c <6.5% in elderly — ACCORD showed increased mortality with intensive control." Include a sliding scale from left to right showing the shift from "benefit of tight control" to "risk of tight control" as health status declines.</image>

Pharmacological Management

Metformin

Metformin remains the cornerstone first-line agent for type 2 diabetes management in older adults, possessing a favorable combination of attributes that make it particularly well-suited for this population. It is weight-neutral, carries no intrinsic risk of hypoglycemia, and is available at low cost. Initiation should begin at a conservative dose of 500 mg daily, with gradual titration to a maximum of 1000 mg twice daily to minimize gastrointestinal side effects. Metformin is contraindicated when the estimated glomerular filtration rate falls below 30 mL/min/1.73 m2, and the dose should be reduced to a maximum of 1000 mg per day when eGFR is between 30 and 45. Gastrointestinal intolerance, manifesting as nausea, diarrhea, and abdominal discomfort, is the most common reason for discontinuation; initiating at low doses, titrating slowly, and using the extended-release formulation can improve tolerability substantially.

An important and underappreciated concern with long-term metformin use is vitamin B12 deficiency, which occurs in 10 to 30 percent of patients on chronic therapy. B12 deficiency contributes to peripheral neuropathy and cognitive impairment, symptoms that may be mistakenly attributed to diabetic complications rather than to the medication itself. Periodic monitoring of B12 levels is therefore essential. The feared complication of lactic acidosis is exceptionally rare, occurring at a rate of approximately 4.3 per 100,000 patient-years, but metformin should be held during episodes of acute illness, administration of iodinated contrast dye, and perioperatively.

SGLT2 Inhibitors

The sodium-glucose cotransporter 2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, have transformed the landscape of diabetes management by demonstrating cardiorenal benefits that extend well beyond glucose lowering. Landmark trials including EMPA-REG OUTCOME, DAPA-CKD, and CREDENCE have established that these agents reduce heart failure hospitalization, slow the progression of chronic kidney disease, and decrease cardiovascular death. These benefits are sufficiently robust that SGLT2 inhibitors are increasingly considered first-line in elderly patients with heart failure or chronic kidney disease regardless of hemoglobin A1c level.

Geriatric-specific concerns with SGLT2 inhibitors warrant careful consideration. Volume depletion and resultant hypotension are clinically significant risks, particularly in elderly patients already taking diuretics or those with marginal oral intake; these medications should be held during acute illness. Genital mycotic infections occur in 5 to 10 percent of patients and may be particularly problematic in those with limited mobility or hygiene capacity. Euglycemic diabetic ketoacidosis, while rare, can occur with reduced carbohydrate intake or during intercurrent illness and may be difficult to recognize given the absence of marked hyperglycemia. Fournier gangrene, an extremely rare but serious necrotizing fasciitis of the perineum, has been reported. SGLT2 inhibitors do not cause hypoglycemia when used as monotherapy. The weight loss they produce, while beneficial for obese patients, may be detrimental in frail elderly individuals at risk for sarcopenia. Dose adjustments reflect the dissociation between glucose-lowering efficacy and cardiorenal protection: empagliflozin and dapagliflozin maintain cardiorenal benefits at eGFR levels as low as 20 mL/min, even though glucose-lowering efficacy diminishes at lower GFR.

GLP-1 Receptor Agonists

The glucagon-like peptide-1 receptor agonists, encompassing semaglutide, liraglutide, dulaglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide, represent another class with demonstrated cardiovascular benefits. The LEADER, SUSTAIN-6, REWIND, and SELECT trials have shown reductions in major adverse cardiovascular events with these agents. Weight loss is significant, ranging from 5 to 15 percent of body weight, which is beneficial in obese diabetic patients but raises legitimate concerns in frail elderly individuals already experiencing or at risk for sarcopenia.

The geriatric-specific considerations for GLP-1 receptor agonists are substantial. Gastrointestinal side effects, including nausea (affecting 15 to 20 percent), vomiting, and diarrhea, may reduce food intake in patients who are already nutritionally compromised. The significant weight loss may accelerate sarcopenia if not accompanied by resistance exercise and adequate protein intake, making this class less suitable for underweight or frail patients. Pancreatitis risk, while rare, should be monitored. These agents do not cause hypoglycemia when used as monotherapy. Oral semaglutide requires administration 30 minutes before the first food, drink, or other medication with no more than 4 ounces of plain water, instructions that may pose compliance challenges for some elderly patients. The overall benefit-risk calculus for GLP-1 receptor agonists shifts unfavorably in frail elderly patients with existing weight loss, and these agents should be used with caution in that context.

DPP-4 Inhibitors

The dipeptidyl peptidase-4 inhibitors, including sitagliptin, linagliptin, saxagliptin, and alogliptin, occupy a particularly valuable niche in geriatric diabetes management. These agents are weight-neutral, carry no risk of hypoglycemia, and are generally well-tolerated, characteristics that make them excellent choices for elderly patients. Their primary limitation is modest glucose-lowering efficacy, with typical hemoglobin A1c reductions of approximately 0.5 to 0.7 percent. Cardiovascular outcome trials have demonstrated safety neutrality (TECOS, CARMELINA), although saxagliptin was associated with an increased risk of heart failure hospitalization in the SAVOR-TIMI 53 trial and should therefore be avoided in patients with heart failure.

Linagliptin is particularly valuable in the geriatric context because it requires no renal dose adjustment, simplifying prescribing in patients with fluctuating or declining kidney function. For frail elderly patients who need modest glycemic improvement with minimal risk, DPP-4 inhibitors are often the best pharmacological choice, providing a gentle and safe addition to the regimen when metformin alone is insufficient.

Sulfonylureas

When cost is a major barrier to pharmacotherapy, sulfonylureas may be considered, but they should be used with full awareness of their hypoglycemia risk. Glipizide is the preferred sulfonylurea in the elderly, prescribed at 2.5 to 10 mg daily; it has a short duration of action and no active metabolites, making it the safest option within this class. Glimepiride, dosed at 1 to 2 mg daily, offers convenient once-daily dosing. Glyburide must be avoided in all elderly patients, as mandated by the Beers Criteria, due to its prolonged duration of action, active metabolites, and the highest hypoglycemia risk among sulfonylureas. All sulfonylureas carry the potential for hypoglycemia, and they are generally less desirable than other agents in older adults.

Thiazolidinediones (Pioglitazone)

Thiazolidinediones should generally be avoided in elderly patients due to the convergence of multiple competing risks. Fluid retention exacerbates heart failure, and these agents are contraindicated in patients with NYHA Class III or IV heart failure. Increased fracture risk, particularly in postmenopausal women, is a significant concern in an osteoporosis-prone population. Weight gain further complicates management. The risk profile of thiazolidinediones in the elderly is sufficiently unfavorable that alternative agents should be preferentially selected.

Insulin

Insulin therapy becomes necessary for many elderly patients with type 2 diabetes as the disease progresses, but the approach to insulin management in this population demands deliberate simplification. Basal insulin is the preferred approach, with options including glargine (U-100 and U-300), detemir, and degludec. Initiation typically begins at 10 units or 0.1 to 0.2 units per kilogram at bedtime, with titration by 2 to 4 units every 3 to 7 days guided by fasting glucose values. Insulin degludec (Tresiba) offers an ultra-long duration of action of approximately 42 hours and was demonstrated in the DEVOTE trial to produce 40 percent less nocturnal hypoglycemia compared with glargine, making it the preferred basal insulin for elderly patients at risk for hypoglycemia. U-300 glargine (Toujeo) provides a flatter pharmacokinetic profile with reduced nocturnal hypoglycemia compared with U-100.

Complex insulin regimens, such as basal-bolus protocols requiring four daily injections, should be reserved exclusively for healthy, motivated, and cognitively intact elderly patients who can reliably manage the demands of carbohydrate counting and dose adjustments. Sliding scale insulin used in isolation must be avoided, as it is reactive rather than proactive, fails to provide glycemic stability, and is listed in the Beers Criteria as potentially inappropriate. Premixed insulin formulations (70/30, 75/25) simplify the regimen to two daily injections but lack flexibility; they are acceptable in elderly patients with stable glycemic patterns. An important and sometimes counterintuitive consideration in elderly patients with chronic kidney disease is that insulin clearance is reduced as kidney function declines, potentially necessitating dose reductions as CKD progresses.

De-intensification and Simplification

Overtreatment of diabetes in the elderly is remarkably common, with approximately 25 percent of elderly patients with hemoglobin A1c below 6.5 percent continuing to receive insulin or sulfonylureas. The SUSTAIN trial demonstrated that de-intensification of diabetes medications in elderly patients with A1c below 7 percent is safe and reduces the incidence of hypoglycemia. The clinical approach to de-intensification involves identifying patients whose A1c is well below their individualized target and systematically reducing or discontinuing sulfonylureas, reducing insulin doses, and simplifying regimens. The overarching priority in geriatric diabetes management is unequivocal: avoiding hypoglycemia takes precedence over achieving any specific hemoglobin A1c target.

<image>A medication selection algorithm for diabetes in elderly patients. Start with "Type 2 DM in elderly patient" and branch based on clinical context. Path 1: "With established ASCVD or high CV risk" → GLP-1 RA (semaglutide, liraglutide) or SGLT2i (empagliflozin, dapagliflozin) + metformin. Path 2: "With HF or CKD" → SGLT2i (first priority) + metformin if eGFR >30. Path 3: "Frail elderly, weight loss concern, primary goal is safety" → DPP-4i (sitagliptin, linagliptin) ± metformin — highlighted as safest option. Path 4: "Need for insulin" → Basal insulin only (degludec or glargine U-300 preferred for lowest hypoglycemia risk). Include a RED "AVOID" box listing: glyburide, sliding scale insulin alone, TZDs, complex basal-bolus regimens in cognitively impaired. Include a GREEN "DE-INTENSIFY" box: if HbA1c <6.5% on insulin/SU → reduce doses; if frail/advanced dementia → relax targets to HbA1c <8.5%; stop unnecessary medications. Show a cost consideration sidebar for patients where affordability is a barrier: metformin + glipizide (low cost) vs. SGLT2i + GLP-1 RA (high cost).</image>

Non-Glycemic Management

Cardiovascular Risk Reduction

The management of cardiovascular risk in elderly diabetic patients encompasses blood pressure control, lipid management, antiplatelet therapy, and the strategic use of agents with proven cardiorenal benefits. Blood pressure targets generally follow the ADA recommendation of less than 130/80 mmHg, although individualization is essential in frail elderly patients where aggressive blood pressure lowering may precipitate orthostatic hypotension and falls. Statin therapy at moderate intensity is recommended for all diabetic patients aged 40 and older, with escalation to high-intensity statin therapy in those with established atherosclerotic cardiovascular disease. In elderly patients over 75 without ASCVD, the decision to initiate statin therapy should involve shared decision-making, though continuation is appropriate for patients already tolerating these medications.

Aspirin use has undergone significant revision in recent years. It remains appropriate for secondary prevention in patients with established cardiovascular disease, but the ASPREE trial conclusively demonstrated no benefit and increased bleeding risk in adults aged 70 and older when used for primary prevention. SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular and renal benefits that are independent of their glucose-lowering effects, reinforcing their role in the comprehensive management of elderly diabetic patients with cardiovascular or renal comorbidities.

Foot Care

Comprehensive foot care is essential for all elderly diabetic patients. An annual comprehensive foot examination should include monofilament testing with a 10-gram monofilament, pulse assessment, and thorough skin and nail inspection. Diabetic neuropathy screening combines the 10-gram monofilament with a 128 Hz tuning fork for vibration perception testing. Charcot arthropathy, foot ulceration, and infection require urgent referral to specialist care. Appropriate footwear, including well-fitting therapeutic shoes, is an important preventive measure, and qualifying patients may access therapeutic shoes through Medicare coverage.

Eye Care

Annual dilated eye examinations are recommended for all diabetic patients. Diabetic retinopathy prevalence increases with disease duration, and the early detection and treatment of retinopathy prevents vision loss. Given the high prevalence of concurrent age-related eye diseases in elderly diabetic patients, comprehensive ophthalmological evaluation serves the dual purpose of monitoring for diabetic eye disease and screening for conditions such as macular degeneration, cataracts, and glaucoma.

Key Clinical Pearls

• Overtreatment of diabetes in elderly is as dangerous as undertreatment — hypoglycemia causes falls, fractures, delirium, cardiac events, and death
• HbA1c <6.5% on insulin or sulfonylureas in an elderly patient is a RED FLAG for overtreatment — de-intensify immediately
• AVOID glyburide in ALL elderly patients (Beers criteria) — if a sulfonylurea is needed, use glipizide
• DPP-4 inhibitors (sitagliptin, linagliptin) are the safest glucose-lowering agents for frail elderly — no hypoglycemia, weight-neutral, well-tolerated, and linagliptin requires no renal adjustment
• SGLT2 inhibitors have cardiorenal benefits regardless of diabetes — they should be considered for ALL elderly diabetics with HF or CKD
• Insulin degludec (Tresiba) has the lowest hypoglycemia risk among basal insulins — preferred in elderly on insulin
• In advanced dementia or end-of-life: the goal is comfort — avoid hypoglycemia, avoid symptomatic hyperglycemia (polyuria, dehydration), stop unnecessary glucose monitoring; HbA1c targets are irrelevant

References

1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
2. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574.
3. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
4. Marso SP, Daniels GH, Tanaka-Masuda K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
5. Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes (WISDM). JAMA. 2020;323(23):2397-2406.

Read this lecture as Markdown